Cell And Gene Therapy Analytics

  1. Regulatory Compliance And Viral Vectors 11/13/2023

    Hear from experts who detail the specific regulatory challenges for advanced therapies, as well as how the regulatory requirements differ in early research and development in academia and in industrial vector production.

  2. Rapid Process Development And Technical Support For AAV Scaleup 12/17/2024

    Accelerate your AAV production journey. Learn how rapid process development and expert support can streamline your path from vial to purified bulk, ensuring scalable and efficient manufacturing.

  3. Innovative Contamination Control: Enabling Integrity And Efficiency 10/15/2024

    An integrated approach can enhance contamination control, boost process efficiency, and ensure the production of high-quality cell therapy products.

  4. Scaling Viral Vectors 11/13/2023

    Industry experts cover the high operational costs associated with viral vectors, along with the challenge presented by their shot shelf life and scalability.

  5. Quality Control Assays 11/13/2023

    Two company leaders detail not only the vectors their respective companies use and why but also the quality control assays performed on viral vectors.

  6. Manufacturing Hurdles With Viral Vectors 11/13/2023

    With a wide range of viral vector-based drugs already approved, viral vectors are expected to remain the primary delivery mechanism for the foreseeable future. However, as the demand for viral vectors increases, addressing the challenges related to their manufacture and scale-up is critical. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share what they consider to be the most difficult challenges in vector development and manufacturing currently.

  7. Analytical Solutions To Help Accelerate Bioprocessing Success 11/1/2024

    Unlock the power of data-driven bioprocessing. Discover how advanced analytics can optimize your cell culture process, improve performance, and accelerate success.

  8. Market Demand For AAV Vectors 11/13/2023

    Here, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO detail the key factors driving the adeno associated virus manufacturing market.

  9. Overcoming Capacity Constraints 11/13/2023

    How can CGT biotechs overcome issues such as building an in house facility and ultimately get their therapies to patients.